918PAtezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): A long-term overall survival (OS) and safety update from the phase III IMvigor211 study

Abstract Background Atezo (anti–PD-L1) is approved for platinum-treated mUC and other indications. Here, we evaluated long-term OS and safety data from IMvigor211, a randomised study evaluating atezo monotherapy vs chemo in platinum-treated mUC (Powles Lancet 2018; primary analysis median follow-up:...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2019-10, Vol.30 (Supplement_5)
Hauptverfasser:	Van der Heijden, M S, Loriot, Y, Duran, I, Ravaud, A, Retz, M M, Vogelzang, N J, Nelson, B, Wang, J, Shen, X, Powles, T
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!